Patents by Inventor Rex Parker

Rex Parker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Serum albumin-binding fibronectin type III domains
    Patent number: 12534511
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: January 27, 2026
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan H. Davis, David Fabrizio
  • SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20220204589
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: November 16, 2021
    Publication date: June 30, 2022
    Inventors: Tracy S. MITCHELL, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan H. Davis, David Fabrizio
  • Serum albumin-binding fibronectin type III domains
    Patent number: 11203630
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: December 21, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan H. Davis, David Fabrizio
  • SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20200048328
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: August 23, 2019
    Publication date: February 13, 2020
    Inventors: Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Rex PARKER, Ray CAMPHAUSEN, Jonathan DAVIS, David FABRIZIO
  • Serum albumin-binding fibronectin type III domains
    Patent number: 10442851
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: October 15, 2019
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Rex Parker, Ray Camphausen, Jonathan Davis, David Fabrizio
  • SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINS
    Publication number: 20170174748
    Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: March 19, 2015
    Publication date: June 22, 2017
    Inventors: Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Rex PARKER, Ray CAMPHAUSEN, Jonathan DAVIS, David FABRIZIO
  • Polynucleotides encoding novel PCSK9 variants
    Publication number: 20080008697
    Abstract: The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Application
    Filed: June 28, 2007
    Publication date: January 10, 2008
    Inventors: Gabriel Mintier, Jian Chen, John Feder, Bowman Miao, Rex Parker
  • Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders
    Patent number: 5348974
    Abstract: This invention relates to the use of tocotrienol, gamma-tocotrienol and delta-tocotrienol in reducing hypercholesterolemia, hyperlipidemia and thromboembolic disorders in mammals. The isolation of these tocotrienols from natural sources and their chemical synthesis is disclosed. The present invention also relates to prodrugs and pharmaceutical compositions of gamma-tocotrienol, delta-tocotrienol and tocotrienol and uses thereof.
    Type: Grant
    Filed: February 10, 1993
    Date of Patent: September 20, 1994
    Assignee: Bristol-Myers Squibb Company
    Inventors: John J. Wright, Bradley C. Pearce, Rex Parker, Asaf A. Qureshi
  • Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders
    Patent number: 5217992
    Abstract: This invention relates to the use of tocotrienol, gamma-tocotrienol and delta-tocotrienol in reducing hypercholesterolemia, hyperlipidemia and thromboembolic disorders in mammals. [The isolation of these tocotrienols from natural sources and their chemical synthesis is disclosed.] The chemical synthesis of these tocotrienols is disclosed. The present invention also relates to prodrugs and pharmaceutical compositions of gamma-tocotrienol, delta-tocotrienol and tocotrienol and uses thereof.
    Type: Grant
    Filed: September 17, 1990
    Date of Patent: June 8, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: John J. Wright, Bradley C. Pearce, Rex Parker, Asaf A. Qureshi